Cancer patients skip trials over fear, not unwillingness, review finds
Analysis of 131 research papers points to distrust, logistics and poor information as obstacles.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
A review of 131 studies on cancer trial participation found that most patients and caregivers stay out because of fear, distrust, logistics and limited information, not a lack of willingness. Separate research on Black Americans, who remain underrepresented in trials, found many are willing to take part when asked.
Why it matters
The findings shift attention toward improving access to trials rather than assuming patients are unwilling to join.
Coverage
- Black patients aren’t avoiding clinical trials–they often ar... (Word in Black)
- Fear, Distrust and Distance: What 131 Studies Reveal About Why Cancer Patients Avoid Clinical Trials (BIOENGINEER.ORG)
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Roche signs $15 billion antibody-drug conjugate deal with Hansoh
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- AstraZeneca enlists Oracle to apply AI in drug trials